Reto Ritschard

893 total citations
11 papers, 482 citations indexed

About

Reto Ritschard is a scholar working on Oncology, Molecular Biology and Biomaterials. According to data from OpenAlex, Reto Ritschard has authored 11 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Biomaterials. Recurrent topics in Reto Ritschard's work include Nanoparticle-Based Drug Delivery (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and HER2/EGFR in Cancer Research (3 papers). Reto Ritschard is often cited by papers focused on Nanoparticle-Based Drug Delivery (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and HER2/EGFR in Cancer Research (3 papers). Reto Ritschard collaborates with scholars based in Switzerland, Finland and United States. Reto Ritschard's co-authors include Christoph Rochlitz, Christoph Mamot, Richard Herrmann, Andreas Wicki, Stefanie Deuster, Lukas Bubendorf, Thomas Dieterle, Willy Küng, Gerhard Christofori and Annette Orleth and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Reto Ritschard

10 papers receiving 476 citations

Peers

Reto Ritschard

BIOMA

ONCOL

RNMI

Joseph G. Reynolds United States

Mark Prytyskach United States

Michiel Bolkestein Netherlands

Di Jiang China

Virginia J. Yao United States

Sukyung Song South Korea

Huafei Li China

Doreen Kunze Germany

Charlene Santos United States

Derek Reichel United States

Joseph G. Reynolds United States

Reto Ritschard

196 ×0.7

BIOMA

191 ×0.7

128 ×0.7

140 ×1.2

ONCOL

134 ×1.6

RNMI

Citations per year, relative to Reto Ritschard Reto Ritschard (= 1×) peers Joseph G. Reynolds

Countries citing papers authored by Reto Ritschard

Since Specialization

Citations

This map shows the geographic impact of Reto Ritschard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reto Ritschard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reto Ritschard more than expected).

Fields of papers citing papers by Reto Ritschard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reto Ritschard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reto Ritschard. The network helps show where Reto Ritschard may publish in the future.

Co-authorship network of co-authors of Reto Ritschard

This figure shows the co-authorship network connecting the top 25 collaborators of Reto Ritschard. A scholar is included among the top collaborators of Reto Ritschard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reto Ritschard. Reto Ritschard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Zingg, Andreas, Reto Ritschard, Helen Thut, et al.. (2025). Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors. Cancer Immunology Research. 13(7). 990–1003.

Wicki, Andreas, Christoph Mamot, Khalil Zaman, et al.. (2021). 268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]. Annals of Oncology. 32. S479–S479. 4 indexed citations

Natoli, Marina, Petra Herzig, Mélanie Buchi, et al.. (2021). Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. Frontiers in Oncology. 11. 644608–644608. 28 indexed citations

Orleth, Annette, Christoph Mamot, Christoph Rochlitz, et al.. (2015). Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. Journal of drug targeting. 24(1). 80–89. 18 indexed citations

Wicki, Andreas, et al.. (2015). Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. International Journal of Pharmaceutics. 484(1-2). 8–15. 31 indexed citations

Mamot, Christoph, Reto Ritschard, Andreas Wicki, et al.. (2012). Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet Oncology. 13(12). 1234–1241. 179 indexed citations

Mamot, Christoph, Reto Ritschard, Andreas Wicki, et al.. (2012). Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting. 20(5). 422–432. 42 indexed citations

Wicki, Andreas, Christoph Rochlitz, Annette Orleth, et al.. (2011). Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth. Clinical Cancer Research. 18(2). 454–464. 77 indexed citations

Mamot, Christoph, Reto Ritschard, Thomas Dieterle, et al.. (2011). A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3029–3029. 9 indexed citations

10.

Mamot, Christoph, Reto Ritschard, Willy Küng, et al.. (2006). EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. Journal of drug targeting. 14(4). 215–223. 51 indexed citations

11.

Boulay, Jean‐Louis, et al.. (1999). Gene Dosage by Quantitative Real-Time PCR. BioTechniques. 27(2). 228–232. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact